GlassScriptPhysician profile
Abilash R Balmuri
NPI 1912107541
$5,585.79
in general payments reported to CMS, 2019-2025
23 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,463 · 2020: $236 · 2021: $55.43 · 2022: $250 · 2023: $213 · 2024: $68.34 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,250 · Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,250.00 |
| Food and Beverage | $331.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $2,277.56 | 2019-2025 | Auryon Laser System 100-120 Vac |
| Cardiovascular Systems INC. | $1,826.13 | 2019-2020 | |
| Abbott Laboratories | $623.18 | 2019-2023 | Mitraclip |
| Bard Peripheral Vascular, INC. | $177.38 | 2020-2024 | Venovo |
| Novartis Pharmaceuticals Corporation | $123.17 | 2019-2021 | |
| Amgen INC. | $82.20 | 2019-2025 | Repatha, Repatha |
| Cardinal Health 200 LLC | $56.01 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.22 | 2019 | |
| Pfizer INC. | $51.27 | 2022-2024 | |
| Abiomed | $45.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.20 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $35.50 | 2022 | |
| Boston Scientific Corporation | $28.27 | 2019-2022 | |
| Acutus Medical, INC. | $21.87 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $19.52 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2023 | Camzyos |
| Penumbra, INC. | $17.56 | 2025 | Penumbra System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.25 | 2025 | Amvuttra |
| Novo Nordisk INC | $15.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.90 | 2021 | |
| Chiesi USA, INC. | $11.98 | 2019 | |
| Lemaitre Vascular, INC. | $8.68 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abilash Balmuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.